It was reported that the cardiac resynchronization therapy defibrillator (crt-d) was exhibiting noise and oversensing on the left ventricular (lv) lead channel.Technical services (ts) examined presenting electrograms (egm) and provided troubleshooting including reprogramming options.There was lv pacing inhibition on the presenting egm, however, none was greater than two seconds.Patient was tested further in clinic and noise could not be reproduced, lv impedance and other measurements were noted to be stable and within normal range, this lv lead is a non-boston scientific product.No adverse patient effects were reported.Currently, the crt-d system remains in service.This report reflects information received by fda in the form of a notification per 803.22 (b)(2).
|